Anxiety and depression among adults with haemophilia A: Patient and physician reported symptoms from the real‐world European CHESS II study
- 20 March 2024
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 30 (3) , 743-751
Abstract
Introduction: The physical pain and disability affecting many people with haemophilia A (PwHA) are known detractors from psychological wellbeing. While psychosocial support is considered a core tenet of the haemophilia comprehensive care structure, the extent to which mental health challenges are detected and monitored by the individuals treating haematologist remains relatively unexplored.Aim: To describe prevalence of anxiety and depression in a real‐world cohort of adult PwHA and evaluate the congruence in reporting of anxiety or depression (A/D) between PwHA and their treating physicians.Methods: Data for PwHA without inhibitors was drawn from the European ‘Cost of Haemophilia: A Socioeconomic Survey II’ (CHESS II) study. Haematologist‐indicated comorbidities of anxiety and depression were unified into a single A/D indicator. The EQ‐5D‐5L health status measure was used to characterise self‐reported A/D, with individuals stratified into two non‐mutually exclusive subgroups based on level of A/D reported (Subgroup A: ‘some’ or above; Subgroup B: ‘moderate’ or above).Result: Of 381 PwHA with evaluable EQ‐5D‐5L responses, 54% (n = 206) self‐reported at least some A/D (Subgroup A) and 17% (n = 66) reported at least moderate A/D (Subgroup B). Patient‐physician congruence in A/D reporting was 53% and 76% for Subgroups A and B, respectively. Descriptive analysis suggested that individuals with physician‐ and/or self‐reported A/D experienced worse clinical outcomes (bleeding events, joint disease, chronic pain).Conclusion: While adverse clinical outcomes appear to correlate with A/D, self‐reports of moderate–severe symptoms occasionally lacked formal recognition from treating physicians. Cross‐disciplinary surveillance of mental health issues could improve both psychological and clinical outcomes among PwHA.Keywords
Funding Information
- Sanofi
- BioMarin Pharmaceutical
This publication has 37 references indexed in Scilit:
- Mental health effects of educationHealth Economics, 2022
- Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsivenessQuality of Life Research, 2021
- Employment status and impact on mental wellbeing in the UK working age population: a cross-sectional analysisThe Lancet, 2019
- Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental healthQuality of Life Research, 2018
- Can The EQ-5D Detect Meaningful Change? A Systematic ReviewPharmacoEconomics, 2015
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Coherence Between Physician Diagnosis and Patient Self Reports of Anxiety and Depression in Primary CareJournal of Nervous & Mental Disease, 2010
- Musculoskeletal Complications of HemophiliaHSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2010
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- The PHQ-9Journal of General Internal Medicine, 2001